Clinical Trials
20
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Advanced MalignanciesMetastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Incyte Biosciences International Sàrl
- Registration Number
- NCT05359692
- Locations
- 🇺🇸
Uab Medicine-the Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸University of California San Diego Medical Center, Moores Cancer Center, La Jolla, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- Incyte Biosciences International Sàrl
- Target Recruit Count
- 176
- Registration Number
- NCT05287113
- Locations
- 🇺🇸
Mayo Clinic Rochester, Scottsdale, Arizona, United States
🇺🇸City of Hope National Medical Center, Long Beach, California, United States
🇺🇸City of Hope Orange County, Irvine, California, United States
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
- Conditions
- Acute Myeloid LeukemiaChronic Phase Chronic Myeloid LeukemiaBlast Phase Chronic Myeloid LeukemiaAcute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaLymphomaLeukemiaSolid TumorsAccelerated Phase Chronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Incyte Biosciences International Sàrl
- Target Recruit Count
- 60
- Registration Number
- NCT03934372
- Locations
- 🇮🇹
Aou Policlinico S. Orsola-Malpighi, Bologna, Italy
🇧🇪Ghent University Hospital, Ghent, Belgium
🇧🇪Universitair Ziekenhuis (Uz) Leuven, Leuven, Belgium
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
- Conditions
- Esophageal CancerMerkel Cell CarcinomaTriple-negative Breast CancerUrothelial CarcinomaMesotheliomaMelanoma (Uveal Melanoma Excluded)Non-small Cell Lung Cancer (NSCLC)Ovarian CancerSquamous Cell Carcinoma of the Head and Neck (SCCHN)Small Cell Lung Cancer (SCLC)
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Incyte Biosciences International Sàrl
- Target Recruit Count
- 22
- Registration Number
- NCT03538028
- Locations
- 🇺🇸
The Angeles Clinic and Research Center, Los Angeles, California, United States
🇺🇸Hackensack Medical Center, Hackensack, New Jersey, United States
🇺🇸Carolina BioOncology Institute, Huntersville, North Carolina, United States
A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"
- Conditions
- BCR-ABL Positive Acute Lymphoblastic Leukemia
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Incyte Biosciences International Sàrl
- Registration Number
- NCT03515785
- Locations
- 🇨🇿
Ihbt/Úhkt, Praha, Czechia
🇫🇷University Hospital Amiens, Amiens, France
🇫🇷University Hospital Angers, Angers, France
- Prev
- 1
- 2
- Next